Axa XL receives €1bn injection as investors await clarity over future direction
Axa’s quarterly results disclosure provided some relief to investors with no change in the French insurer’s previously disclosed Covid-19 estimate of €1.5bn ($1.75bn) and further indications of performance improvement within its Axa XL division.
If you are a subscriber, please sign back in to read this article
If you are not currently a subscriber please see contact details below